Instrument Inactif

Communiqués Titan Pharmaceuticals, Inc. OTC Bulletin Board

Actions

TTNP

US8883141017

Communiqués

15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
27/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ
11/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock	AQ
20/03/25	Titan Pharmaceuticals: Q4 Earnings Snapshot	AQ
03/01/25	Titan Pharmaceuticals: Q3 Earnings Snapshot	AQ
03/01/25	Titan Pharmaceuticals : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
27/11/24	Titan Pharmaceuticals : Announces Receipt of Notice from Nasdaq Form 8 K	PU
27/11/24	Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq	AQ
22/08/24	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
19/08/24	Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.	AQ
15/08/24	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
16/05/24	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ
01/04/24	Titan Pharmaceuticals : Non-Reliance on Previously Issued Financial Report - Form 8-K	PU
21/03/24	Titan Pharmaceuticals : Private Placement - Form 8-K	PU
25/01/24	Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria	AQ
29/12/23	Titan Pharmaceuticals Announces Reverse Stock Split and Ratio - December 28, 2023	AQ
28/12/23	Titan Pharmaceuticals Announces Reverse Stock Split and Ratio	AQ
15/11/23	Titan Pharmaceuticals: Q3 Earnings Snapshot	AQ
16/10/23	Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors	AQ
18/09/23	Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock	AQ
08/09/23	TITAN PHARMACEUTICALS : UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION - Form 8-K	PU
15/08/23	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ